Skip to main content
Premium Trial:

Request an Annual Quote

AstraZeneca Will Use EpiStem's 'Plucked Hair' Technology to Study Biomarkers in Cancer Rx Research

NEW YORK (GenomeWeb News) — EpiStem, a UK company focused on developing epithelial stem cells from human hair, said today it has partnered with AstraZeneca to conduct feasibility studies for a biomarker program that may help the drug developer in preclinical and clinical cancer drug studies.
 
EpiStem’s so-called “plucked hair” approach is a biomarker program based on a “link between the stem cells in the small intestine and the hair follicle,” the company said. The biomarker now has been developed into “a non-invasive tool to measure drug effects on adult epithelial stem cells and tissues.”
 
The technology analyzes changes in gene expression that may be found in hairs plucked from human cancer patients in various phases of treatment. These changes can offer researchers information such as the “measure of drug exposure, toxicity, dose/schedule, and patient selection,” the company said.
 
Because it is non-invasive, the company said, this methodology may be particularly useful in assessing drugs in preclinical development, “thereby assisting go/no go decisions” about drug development and reducing risk and expense of a drug failing in the clinical trial phase.
 
Brent Vose, AstraZeneca’s vice president of oncology therapies, said minimally invasive biomarkers are “an important step” for their oncology drug programs, and said his company has been “impressed by the plucked hair biomarker technology.”
 
Jeff Moore, managing director of EpiStem’s novel technologies program, said the US Food and Drug Administration “has made it clear that they want new drugs to have biomarkers that show the direct impact of the drug.”
 
Moore also said that “at this stage of our development” the company will not make predictions about the program’s commercial value.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.